FYI | INSM Message Board Posts

Insmed Incorporated

  INSM website
  • Membership Drive Update: In the first 48 hours we've hit almost 20% of our goal. An encouraging start to be sure, but we can't stop now. We need to pull enough subscription revenue forward to counter severe cash flow deficits resulting from a dramatic slow-down in ad spend thanks to the global pandemic which shows no signs of letting up in the near-term. We're doing everything in our power to keep our heads above some very choppy water, but we can't do it alone. We need your help. So if you've ever thought about giving our premium service a try, there's no better time to do it than right now by taking advantage of one of our discounted multi-year plans. Thanks in advance for your continued loyalty & support! 

  • Limited Premium Membership Offer
    Choose a Plan, Save Money & Help Us Survive the Pandemic

    Lifetime @ $399 (only 24 left) 5-yrs @ $199 (only 30 left) 2-yrs @ $99 (only 27 left)

INSM   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  46258 of 53596  at  6/13/2019 7:17:20 PM  by

slimhere


FYI

Savara Down 75% After Study Doesn't Meet Primary Endpoint >SVRA

10:44 am ET June 13, 2019 (Dow Jones) Print

By Michael Dabaie

Savara Inc. (SVRA) shares fell 75% to $2.61 Thursday morning.

The orphan lung disease company said Wednesday the IMPALA Phase 3 study of Molgradex to treat autoimmune alveolar pulmonary proteinosis didn't meet its primary endpoint of alveolar-arterial oxygen gradient.

The study showed statistically significant improvement in the St. George's Respiratory Questionnaire, a key secondary endpoint, the company said.

The company said it plans to meet with the U.S. Food and Drug Administration and European Medicines Agency in the coming months to discuss the data and path forward.

JMP Securities cut Savara to Market Perform from Outperform.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

June 13, 2019 10:44 ET (14:44 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 242
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






Financial Market Data provided by
.


Loading...